Affimed (AFMD) Competitors

Affimed (NASDAQ:AFMD) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Does the media favor AFMD or ABOS?

In the previous week, Affimed had 3 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 5 mentions for Affimed and 2 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 1.82 beat Affimed's score of 0.55 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Affimed	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Is AFMD or ABOS more profitable?

Acumen Pharmaceuticals has a net margin of 0.00% compared to Affimed's net margin of -7,836.26%. Acumen Pharmaceuticals' return on equity of -32.99% beat Affimed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Affimed	-7,836.26%	-193.84%	-107.24%
Acumen Pharmaceuticals	N/A	-32.99%	-27.99%

Do insiders and institutionals hold more shares of AFMD or ABOS?

30.8% of Affimed shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 3.8% of Affimed shares are owned by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer AFMD or ABOS?

Affimed received 412 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. However, 72.97% of users gave Acumen Pharmaceuticals an outperform vote while only 69.79% of users gave Affimed an outperform vote.

Company	Underperform	Outperform
Affimed	Outperform Votes 439 69.79%	Underperform Votes 190 30.21%
Acumen Pharmaceuticals	Outperform Votes 27 72.97%	Underperform Votes 10 27.03%

Which has more risk and volatility, AFMD or ABOS?

Affimed has a beta of 2.28, suggesting that its share price is 128% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.

Do analysts prefer AFMD or ABOS?

Affimed currently has a consensus price target of $13.50, suggesting a potential upside of 1,127.27%. Acumen Pharmaceuticals has a consensus price target of $7.33, suggesting a potential upside of 588.58%. Given Affimed's higher probable upside, equities analysts plainly believe Affimed is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affimed	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Acumen Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Which has stronger valuation & earnings, AFMD or ABOS?

Acumen Pharmaceuticals has lower revenue, but higher earnings than Affimed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affimed	$877K	20.19	-$114.66M	N/A	N/A
Acumen Pharmaceuticals	N/A	N/A	-$52.37M	-$1.71	-0.62

Summary

Acumen Pharmaceuticals beats Affimed on 10 of the 16 factors compared between the two stocks.